150 related articles for article (PubMed ID: 22277584)
1. A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.
Smith JP; Harms JF; Matters GL; McGovern CO; Ruggiero FM; Liao J; Fino KK; Ortega EE; Gilius EL; Phillips JA
Cancer Biol Ther; 2012 Feb; 13(3):164-74. PubMed ID: 22277584
[TBL] [Abstract][Full Text] [Related]
2. Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival.
Smith JP; Whitcomb DC; Matters GL; Brand RE; Liao J; Huang YJ; Frazier ML
Pancreas; 2015 Mar; 44(2):236-42. PubMed ID: 25469546
[TBL] [Abstract][Full Text] [Related]
3. A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort.
Balázs A; Németh BC; Ördög B; Hegyi E; Hritz I; Czakó L; Czimmer J; Gódi S; Csiszkó A; Rakonczay Z; Párniczky A; Izbéki F; Halász A; Kahán Z; Hegyi P; Sahin-Tóth M;
Pancreas; 2016 Apr; 45(4):541-5. PubMed ID: 26646278
[TBL] [Abstract][Full Text] [Related]
4. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
[TBL] [Abstract][Full Text] [Related]
5. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous expression of cholecystokinin and gastrin receptor in stomach and pancreatic cancer: An immunohistochemical study.
Rai R; Kim JJ; Tewari M; Shukla HS
J Cancer Res Ther; 2016; 12(1):411-6. PubMed ID: 27072272
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
9. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
10. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer.
Nie H; Huang PQ; Jiang SH; Yang Q; Hu LP; Yang XM; Li J; Wang YH; Li Q; Zhang YF; Zhu L; Zhang YL; Yu Y; Xiao GG; Sun YW; Ji J; Zhang ZG
Theranostics; 2021; 11(8):3898-3915. PubMed ID: 33664869
[TBL] [Abstract][Full Text] [Related]
11. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
[TBL] [Abstract][Full Text] [Related]
12. CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome.
Shamai S; Nabiochtchikov I; Kraus S; Zigdon S; Kazanov D; Itzhak-Klutch M; Eizner C; Arber N; Geva R
PLoS One; 2015; 10(9):e0134469. PubMed ID: 26394139
[TBL] [Abstract][Full Text] [Related]
13. A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4.
Yang K; He M; Cai Z; Ni C; Deng J; Ta N; Xu J; Zheng J
Pancreas; 2015 Apr; 44(3):370-9. PubMed ID: 25522282
[TBL] [Abstract][Full Text] [Related]
14. Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma.
Radulovich N; Leung L; Ibrahimov E; Navab R; Sakashita S; Zhu CQ; Kaufman E; Lockwood WW; Thu KL; Fedyshyn Y; Moffat J; Lam WL; Tsao MS
Oncogene; 2015 Aug; 34(32):4238-47. PubMed ID: 25381825
[TBL] [Abstract][Full Text] [Related]
15. Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival.
El Jellas K; Hoem D; Hagen KG; Kalvenes MB; Aziz S; Steine SJ; Immervoll H; Johansson S; Molven A
Cancer Med; 2017 Jul; 6(7):1531-1540. PubMed ID: 28556564
[TBL] [Abstract][Full Text] [Related]
16. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.
Stracquadanio G; Vrugt B; Flury R; Schraml P; Würl P; Müller TH; Knippschild U; Henne-Bruns D; Breitenstein S; Clavien PA; Graf R; Bond GL; Grochola LF
Clin Cancer Res; 2016 Dec; 22(24):6069-6077. PubMed ID: 27283965
[TBL] [Abstract][Full Text] [Related]
17. Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome.
Kim JC; Kim KT; Park JT; Kim HJ; Sato Y; Kim HS
Hepatogastroenterology; 2015; 62(138):251-6. PubMed ID: 25916042
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
19. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
